Online citations, reference lists, and bibliographies.
← Back to Search

Recent Findings And Future Directions For Interpolar Mitotic Kinesin Inhibitors In Cancer Therapy

S. Myers, I. Collins
Published 2016 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The kinesin class of microtubule-associated motor proteins present attractive anti-cancer targets owing to their roles in key functions in dividing cells. Two interpolar mitotic kinesins Eg5 and HSET have opposing motor functions in mitotic spindle assembly with respect to microtubule movement, but both offer opportunities to develop cancer selective therapeutic agents. Here, we summarize the progress to date in developing inhibitors of Eg5 and HSET, with an emphasis on structural biology insights into the binding modes of allosteric inhibitors, compound selectivity and mechanisms of action of different chemical scaffolds. We discuss translation of preclinical studies to clinical experience with Eg5 inhibitors, recent findings on potential resistance mechanisms, and explore the implications for future anticancer drug development against these targets.
This paper references
10.1016/0092-8674(95)90142-6
Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo
A. Blangy (1995)
10.1038/45483
A structural change in the kinesin motor protein that drives motility
Sarah Rice (1999)
10.1083/JCB.147.2.351
The Kinesin-Related Protein, Hset, Opposes the Activity of Eg5 and Cross-Links Microtubules in the Mammalian Mitotic Spindle
V. Mountain (1999)
Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based
TU Mayer (1999)
10.1074/jbc.M100395200
Crystal Structure of the Mitotic Spindle Kinesin Eg5 Reveals a Novel Conformation of the Neck-linker*
J. Turner (2001)
10.1083/jcb.200204155
Human TPX2 is required for targeting Aurora-A kinase to the spindle
T. Kufer (2002)
10.1021/BI026716J
Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
S. Debonis (2003)
The Vinca Alkaloids. Holland-Frei cancer medicine
E. Rowinksy (2003)
10.1016/J.JMB.2003.10.074
Inhibition of a mitotic motor protein: where, how, and conformational consequences.
Y. Yan (2004)
10.1074/jbc.M413140200
Monastrol Inhibition of the Mitotic Kinesin Eg5*
J. C. Cochran (2005)
10.1016/J.BMCL.2005.02.055
Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.
C. Cox (2005)
10.1091/MBC.E05-02-0167
Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference.
Changjun Zhu (2005)
10.1002/cbic.200500005
Development and Biological Evaluation of Potent and Specific Inhibitors of Mitotic Kinesin Eg5
M. Gartner (2005)
A resistance mechanism for the KSP inhibitor ispinesib implicates point mutations in the compound binding site
J R Jackson (2005)
A resistance mechanism for the KSP inhibitor ispinesib implicates point mutations in the compound binding site; Proceedings of the AACNCIEORTC Molecular Targets and Cancer Therapeutics
Jackson (2005)
10.1158/0008-5472.CAN-05-1531
Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development.
E. Koller (2006)
10.1007/978-1-59745-035-5_18
Resistance To Taxanes
L. Greenberger (2006)
10.1074/jbc.M511735200
S-Trityl-L-cysteine Is a Reversible, Tight Binding Inhibitor of the Human Kinesin Eg5 That Specifically Blocks Mitotic Progression*
D. Skoufias (2006)
A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer
J. Jackson (2006)
10.1016/J.JMB.2006.04.062
Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
Sébastien Brier (2006)
10.1074/jbc.M511955200
A Pathway of Structural Changes Produced by Monastrol Binding to Eg5*
Z. Maliga (2006)
10.4161/cc.5.19.3255
Regulation and Targeting of Eg5, a Mitotic Motor Protein in Blast Crisis CML: Overcoming Imatinib Resistance
B. Carter (2006)
10.1016/J.LUNGCAN.2006.06.018
Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy.
T. Saijo (2006)
Resistance to taxanes. Cancer drug discovery and development: Cancer drug resistance
L. Greenberger (2006)
10.1038/sj.bjp.0707308
Chemogenomic approaches to drug discovery: similar receptors bind similar ligands
T. Klabunde (2007)
10.1038/NCHEMBIO.2007.34
ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
L. Luo (2007)
10.2174/138620707782507313
Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint.
A. Bender (2007)
10.1016/J.BMCL.2007.04.101
Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors.
N. Ogo (2007)
10.1074/jbc.M608883200
Structure of Human Eg5 in Complex with a New Monastrol-based Inhibitor Bound in the R Configuration*
I. Garcı́a-Sáez (2007)
10.1158/0008-5472.CAN-07-0326
Overexpression of Eg5 causes genomic instability and tumor formation in mice.
A. Castillo (2007)
[Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen].
M. Kinoshita (2007)
10.1016/J.BMCL.2007.04.076
Synthesis and SAR of thiophene containing kinesin spindle protein (KSP) inhibitors.
A. Pinkerton (2007)
10.1016/j.bbrc.2008.05.074
Crystal structure of HsEg5 in complex with clinical candidate CK0238273 provides insight into inhibitory mechanism, potency, and specificity.
B. Zhang (2008)
10.1021/jm070606z
Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.
S. Debonis (2008)
10.1101/gad.1700908
Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes.
M. Kwon (2008)
10.1021/jm800386y
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.
C. Cox (2008)
10.1158/1078-0432.CCR-08-0120
Targeting the Kinesin Spindle Protein: Basic Principles and Clinical Implications
V. Sarli (2008)
10.1002/pros.20783
Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity
Norihiro Hayashi (2008)
Discovery of a novel Eg5 kinesin inhibitor, ARQ 621, with potent antitumor activity while sparing bone marrow-derived cells
S Jeay (2008)
Kinesin spindle protein (KSP) inhibitors
CD Cox (2008)
10.1016/j.bmcl.2009.05.040
Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.
Brian R. Lahue (2009)
10.1091/mbc.E08-09-0971
Kinesin-14 family proteins HSET/XCTK2 control spindle length by cross-linking and sliding microtubules.
Shang Cai (2009)
10.1016/j.cub.2009.08.027
Kif15 Cooperates with Eg5 to Promote Bipolar Spindle Assembly
M. Tanenbaum (2009)
10.1016/j.bmcl.2009.01.018
Bis(hetero)aryl derivatives as unique kinesin spindle protein inhibitors.
K. Matsuno (2009)
10.1158/1078-0432.CCR-08-2124
The Expression of Three Genes in Primary Non–Small Cell Lung Cancer Is Associated with Metastatic Spread to the Brain
Helena Grinberg-Rashi (2009)
10.1042/BJ20091207
An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex.
H. Kaan (2009)
10.1002/cm.20392
Structures of kinesin motor proteins.
A. Marx (2009)
10.1021/bi900946r
Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.
Payal R. Sheth (2009)
10.1016/j.cub.2009.09.019
The Role of Hklp2 in the Stabilization and Maintenance of Spindle Bipolarity
David Vanneste (2009)
10.4161/cc.8.7.7950
Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5
Santiago Rello-Varona (2009)
Structures of kinesin motor proteins. Cell Motil Cytoskel
A Marx (2009)
10.1016/j.bmcl.2009.11.012
The discovery of tetrahydro-beta-carbolines as inhibitors of the kinesin Eg5.
P. Barsanti (2010)
10.2174/187152010794479807
Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
C. Cox (2010)
10.1016/j.cub.2010.03.067
Proper Organization of Microtubule Minus Ends Is Needed for Midzone Stability and Cytokinesis
Shang Cai (2010)
10.1073/pnas.0915068107
Antitumor activity of an allosteric inhibitor of centromere-associated protein-E
K. W. Wood (2010)
10.1016/j.bmcl.2010.01.110
The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5.
K. Schiemann (2010)
10.1371/journal.pcbi.1000845
Predicting Important Residues and Interaction Pathways in Proteins Using Gaussian Network Model: Binding and Stability of HLA Proteins
T. Haliloglu (2010)
10.1016/j.bcp.2009.11.001
Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.
Sergey O Tcherniuk (2010)
10.1021/jm100421n
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
H. Kaan (2010)
10.1038/nature08833
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
G. Hatzivassiliou (2010)
10.1002/path.2706
Ectopic expression of the microtubule‐dependent motor protein Eg5 promotes pancreatic tumourigenesis
Min Liu (2010)
10.1016/j.semcdb.2010.01.018
How kinesin motor proteins drive mitotic spindle function: Lessons from molecular assays.
L. Wordeman (2010)
10.1038/nature08902
RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
P. Poulikakos (2010)
10.1021/bi1005283
Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain.
Payal R. Sheth (2010)
10.1124/mi.11.2.12
Spindle poisons and cell fate: a tale of two pathways.
Daniel R Matson (2011)
10.1021/jm200629m
Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent.
Maria-Elena Theoclitou (2011)
10.1038/nrclinonc.2010.228
Mitosis is not a key target of microtubule agents in patient tumors
E. Komlódi-Pásztor (2011)
10.1124/MI.11.2.12
Spindle Poisons and Cell Fate: A Tale of Two Pathways
M. Dr (2011)
10.1021/jm200448n
Structure-activity relationships of carboline and carbazole derivatives as a novel class of ATP-competitive kinesin spindle protein inhibitors.
Tomoki Takeuchi (2011)
10.1111/j.1442-2042.2011.02751.x
Overexpression of Eg5 predicts unfavorable prognosis in non‐muscle invasive bladder urothelial carcinoma
S. Ding (2011)
10.1016/j.jtbi.2011.08.017
Analysis of the interaction of the Eg5 Loop5 with the nucleotide site.
Timothy D. Harrington (2011)
10.1016/j.semcdb.2011.09.023
Elucidating the functionality of kinesins: an overview of small molecule inhibitors.
James A. D. Good (2011)
10.1021/jm100991m
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
H. Kaan (2011)
10.1016/j.bpj.2011.10.032
The loop 5 element structurally and kinetically coordinates dimers of the human kinesin-5, Eg5.
Joshua S. Waitzman (2011)
10.1021/jm201195m
Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity†
F. Wang (2012)
10.1038/nrc3310
Kinesins and cancer
Oliver Rath (2012)
10.1158/1078-0432.CCR-11-0999
Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
E. Komlódi-Pásztor (2012)
10.1242/jcs.107474
Acentrosomal spindle organization renders cancer cells dependent on the kinesin HSET
J. Kleylein-Sohn (2012)
10.3109/10428194.2011.619018
A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines
A. Chowdhury (2012)
10.1534/genetics.111.128710
Mitotic Spindle Form and Function
M. Winey (2012)
10.1107/S0907444912027965
The structure of the ternary Eg5–ADP–ispinesib complex
S. Talapatra (2012)
10.1038/cdd.2012.61
Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy
A. Ogden (2012)
10.1371/journal.pcbi.1003329
Mapping the Structural and Dynamical Features of Kinesin Motor Domains
Guido Scarabelli (2013)
10.1021/jm3014597
Optimized S-Trityl-l-cysteine-Based Inhibitors of Kinesin Spindle Protein with Potent in Vivo Antitumor Activity in Lung Cancer Xenograft Models
James A. D. Good (2013)
10.1016/j.coph.2013.06.004
Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology.
P. Workman (2013)
10.1021/ja310377d
Structural insights into a unique inhibitor binding pocket in kinesin spindle protein.
V. Ulaganathan (2013)
10.1182/BLOOD.V122.21.285.285
Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study
J. Shah (2013)
10.1016/j.gene.2013.08.004
Kinesin-5: cross-bridging mechanism to targeted clinical therapy.
E. Wojcik (2013)
10.1007/s12032-013-0476-0
The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma
Dingqi Sun (2013)
10.1016/j.ejmech.2013.01.031
Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.
H. B. El-Nassan (2013)
10.1182/blood-2013-09-522409
"A fortuitous combination of circumstances".
S. Lonial (2013)
10.1021/cb400186w
Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1.
Jiaquan Wu (2013)
10.1007/s10637-013-0026-9
A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
A. Hollebecque (2013)
10.1021/jm401071u
Resistance by allostery: a novel perspective for eg5-targeted drug design.
Ambily Nath Indu Viswanath (2013)
10.1002/jcp.24103
Kinesin spindle protein SiRNA slows tumor progression
E. Marra (2013)
10.1016/j.chembiol.2013.09.012
Design, Synthesis, and Biological Evaluation of an Allosteric Inhibitor of HSET that Targets Cancer Cells with Supernumerary Centrosomes
Ciorsdaidh A. Watts (2013)
10.1038/499291a
Cancer: Calculated treatment
N. Komarova (2013)
10.1016/j.bcp.2013.09.003
STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
Rose-Laure Indorato (2013)
10.1021/ja401540g
Adenosine triphosphate hydrolysis mechanism in kinesin studied by combined quantum-mechanical/molecular-mechanical metadynamics simulations.
M. McGrath (2013)
10.1021/jm4006274
Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism.
S. Talapatra (2013)
10.1186/1757-2215-7-53
KIFCI, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitries
Shrikant Pawar (2014)
10.1107/S1399004713028721
The crystal structure and biochemical characterization of Kif15: a bifunctional molecular motor involved in bipolar spindle formation and neuronal development
M. Klejnot (2014)
10.1016/j.cub.2014.09.011
Mitotic Kinesins: A Reason to Delve into Kinesin-12
W. Hancock (2014)
10.1016/j.molonc.2014.05.007
Synergism between inhibitors of Aurora A and KIF11 overcomes KIF15‐dependent drug resistance
H. T. Ma (2014)
10.1038/nrm3768
Prime movers: the mechanochemistry of mitotic kinesins
R. Cross (2014)
10.1007/s00280-014-2467-z
A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors
H. Wakui (2014)
10.1021/jm501179r
Discovery of potent KIFC1 inhibitors using a method of integrated high-throughput synthesis and screening.
Bin Yang (2014)
10.1021/ml500016j
Kinesin spindle protein inhibitors with diaryl amine scaffolds: crystal packing analysis for improved aqueous solubility.
Tomoki Takeuchi (2014)
10.1158/1078-0432.CCR-14-3252
Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent
Nicholas F. Dybdal-Hargreaves (2015)
10.1016/j.canlet.2015.02.040
Pgp efflux pump decreases the cytostatic effect of CENP-E inhibitor GSK923295.
Sergey O. Tcherniuk (2015)
10.1007/s10637-015-0211-0
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
P. LoRusso (2015)
10.1200/JCO.2015.33.15_SUPPL.2528
Overcoming the proliferation rate paradox: Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205.
K. Mross (2015)
10.1080/15384047.2015.1070980
KIFC1 is a novel potential therapeutic target for breast cancer
Y. Li (2015)
10.1021/cb500939x
Structural basis of new allosteric inhibition in Kinesin spindle protein Eg5.
H. Yokoyama (2015)
10.1007/978-94-017-9732-0_2
The discovery and development of Eg5 inhibitors for the clinic
James A. D. Good (2015)
10.1016/j.ccell.2014.11.006
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
M. R. Girotti (2015)
10.1021/acsmedchemlett.5b00221
Structure-Guided Design of Novel l-Cysteine Derivatives as Potent KSP Inhibitors.
N. Ogo (2015)
10.1038/bjc.2015.264
Hitting the brakes: targeting microtubule motors in cancer
G. Chandrasekaran (2015)
10.18632/ONCOTARGET.3475
HSET overexpression fuels tumor progression via centrosome clustering-independent mechanisms in breast cancer patients
V. Pannu (2015)
The discovery and development of Eg5 inhibitors for the clinic. Kinesins and cancer
Good (2015)
manuscript; available in PMC
b Microtubule-stimulated ATPase activity expressed as Ki app



This paper is referenced by
10.3390/ijms22126420
Mechanisms by Which Kinesin-5 Motors Perform Their Multiple Intracellular Functions
Himanshu Pandey (2021)
10.1107/S2059798321000176
Structure and comparison of the motor domain of centromere-associated protein E
A. Shibuya (2021)
10.3390/ph14050442
The Chemistry Behind ADCs
V. Kostova (2021)
10.1016/j.biomaterials.2021.120793
Systemic delivery of CRISPR/Cas9 to hepatic tumors for cancer treatment using altered tropism of lentiviral vector.
Sungjin Lee (2021)
10.1152/physrev.00006.2020
Development and Physiological Functions of the Lymphatic System - Insights from Genetic Studies of Lymphedema.
S. Martin-Almedina (2021)
10.1039/d0sc06223e
Total synthesis of biselide A†
Venugopal Rao Challa (2021)
10.1101/2021.01.26.428220
Molecular mechanism of a parasite kinesin motor and implications for its inhibition
A. Cook (2021)
10.1016/j.csbj.2021.04.036
CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer
Desh Deepak Singh (2021)
10.1016/j.jbc.2021.101063
Cryo-EM structure of a microtubule-bound parasite kinesin motor and implications for its mechanism and inhibition.
Alexander D. Cook (2021)
Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
Bruna Cândido Guido (2021)
10.1186/s13008-020-00063-4
Kinesin-5 Eg5 is essential for spindle assembly and chromosome alignment of mouse spermatocytes
Zhen-Yu She (2020)
10.21037/tcr-20-1937
KIF4A is a promising prognostic marker and correlates with immune infiltration in clear cell renal cell carcinoma
Canxuan Li (2020)
10.1186/s12199-020-00871-8
Identification by TCGA database search of five genes that are aberrantly expressed and involved in hepatocellular carcinoma potentially via DNA methylation changes
Junya Matsushita (2020)
10.1136/jmedgenet-2019-106769
‘Kinesinopathies’: emerging role of the kinesin family member genes in birth defects
Silvia Kalantari (2020)
10.4155/fmc-2019-0256
New pharmacological findings linked to biphenyl DHPMs, kinesin Eg5 ligands: anticancer and antioxidant effects.
I. Gonçalves (2020)
10.1021/acs.inorgchem.0c00957
Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands
Michał Łomzik (2020)
10.4251/wjgo.v12.i3.276
Increased KIF21B expression is a potential prognostic biomarker in hepatocellular carcinoma
Hui-Qi Zhao (2020)
10.3390/cancers12113464
IL3RA-Targeting Antibody–Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies
D. Kirchhoff (2020)
10.1097/MD.0000000000019011
Preliminary study on the clinical significance of kinesin Kif18a in nonsmall cell lung cancer
WeiFeng Guo (2020)
10.1007/s43440-020-00154-7
Thiadiazole derivatives as anticancer agents
M. Szeliga (2020)
10.1093/hmg/ddaa018
A mouse model for Kinesin Family Member 11 (Kif11)-associated familial exudative vitreoretinopathy.
Yanshu Wang (2020)
10.1002/ardp.202000060
Design, synthesis, and molecular docking study of new monastrol analogues as kinesin spindle protein inhibitors.
M. H. El-Hamamsy (2020)
10.1016/j.canlet.2019.12.042
TRIM8 interacts with KIF11 and KIFC1 and controls bipolar spindle formation and chromosomal stability.
Santina Venuto (2020)
10.1016/j.jconrel.2020.02.013
KSP siRNA/paclitaxel-loaded PEGylated cationic liposomes for overcoming resistance to KSP inhibitors: Synergistic antitumor effects in drug-resistant ovarian cancer.
Jinju Lee (2020)
10.3390/genes11080921
CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials
Khalil Khalaf (2020)
Biochemical characterisation of human KifC1 and Eg5, two potential targets for drug development in cancer chemotherapy
C. Tham (2019)
10.1016/j.canlet.2018.10.005
Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.
Ana C. Henriques (2019)
10.1002/minf.201900035
Benserazide Perturbs Kif15‐kinesin Binding Protein Interaction with Prolonged Metaphase and Defects in Chromosomal Congression: A Study Based on in silico Modeling and Cell Culture
Jomon Sebastian (2019)
10.1016/j.bmc.2019.115154
Kolavenic acid analog restores growth in HSET-overproducing fission yeast cells and multipolar mitosis in MDA-MB-231 human cells.
Naoaki Kurisawa (2019)
10.1093/jb/mvz015
Morelloflavone as a novel inhibitor of mitotic kinesin Eg5.
T. Ogunwa (2019)
10.1016/j.bbrc.2019.09.028
Identification of benzo[d]pyrrolo[2,1-b]thiazole derivatives as CENP-E inhibitors.
M. Yamane (2019)
10.3390/molecules24183295
Antiproliferative S-Trityl-l-Cysteine -Derived Compounds as SIRT2 Inhibitors: Repurposing and Solubility Enhancement
M. Radwan (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar